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STUDY QUESTIONS: Does the application of anti-adhesion gel, compared to no gel, following operative hysteroscopy to treat
intrauterine pathology in women wishing to conceive increase the chance of conception leading to live birth?
WHAT IS KNOWN ALREADY: Intrauterine adhesions (IUAs) following operative hysteroscopy may impair reproductive success in
women of reproductive age. Anti-adhesion barrier gels may decrease the occurrence of IUAs, but the evidence on their effectiveness to
improve reproductive outcomes is sparse and of low quality.
STUDY DESIGN, SIZE, DURATION: This multicentre, parallel group, superiority, blinded and pragmatic randomised controlled trial
is being carried out in seven participating centres in Belgium. Recruitment started in April 2019. Women will be randomly allocated to
treatment with anti-adhesion gel (intervention group) or no gel (control group). Sterile ultrasound gel will be applied into the vagina as a
mock-procedure in both treatment arms. The patient, fertility physician and gynaecologist performing the second-look hysteroscopy
are unaware of the allocated treatment. Power analysis, based on a target improvement of 15% in conception leading to live birth using
anti-adhesion gel, a power of 85%, a significance level of 5%, and a drop-out rate of 10%, yielded a number of 444 patients to be
randomised. The baseline rate of conception leading to live birth in the control group is expected to be 45%.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Women of reproductive age (18–47 years), wishing to conceive (spontane-
ously or by fertility treatment) and scheduled for operative hysteroscopy to treat intrauterine pathology (endometrial polyps, myomas with
uterine cavity deformation, uterine septa, IUAs or retained products of conception) are eligible for recruitment. Women may try to
conceive from 3 to 6 weeks after receiving allocated treatment with follow-up ending at 30 weeks after treatment. If the woman fails to
conceive within this timeframe, a second-look hysteroscopy will be scheduled within 2–6 weeks to check for IUAs. The primary endpoint
is conception leading to live birth, measured at 30 weeks after randomisation. The secondary endpoints are time to conception, clinical
pregnancy, miscarriage and ectopic pregnancy rates, measured at 30 weeks after receiving allocated treatment. The long-term follow-up
starts when the patient is pregnant and she will be contacted every trimester.
VC The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
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Introduction
Several intrauterine anomalies, including endometrial polyps, myomas
with uterine cavity deformation, uterine septa, IUAs and retained
products of conception (RPOC), have been linked with female fertility
problems (Kodaman and Arici, 2007; Chan et al., 2011; Bosteelset al.,
2018; Kliman and Frankfurter, 2019). Hysteroscopy is considered to
be the gold standard to treat these intrauterine pathologies. The evi-
dence in favour of operative hysteroscopy for improving reproductive
success in women with endometrial polyps, myomas with uterine
cavity deformation, uterine septa, IUAs or RPOC is sparse and of
moderate to low quality. Nevertheless, hysteroscopy is very often per-
formed, especially in women attending fertility clinics because among
the medical community the presence of intrauterine pathology distort-
ing the uterine is widely believed to impair reproductive outcome.
A major long-term complication of operative hysteroscopy is the for-
mation of IUAs (Taskin et al., 2000; Hanstedeet al., 2015; Hamerlynck
et al., 2016). The reported incidence of postsurgical IUAs at second-
look hysteroscopy is 3.6% after polypectomy, 6.7% after resection of
uterine septa, 31% after removal of a solitary myoma, 45% after resec-
tion of multiple myomas and 3% after removal of RPOC.
IUAs are fibrous strings at opposing walls of the uterus, develop-
ing after injury to the basal layer of the endometrium (Deans and
Abbott, 2010; Salazar et al., 2017). Reviews of large observational
studies have demonstrated an association between IUAs and poor
reproductive outcome, namely a prevalence of infertility as high as
43% and recurrent pregnancy loss in 22% (Schenker and Margalioth,
1982; Ventoliniet al., 2004; Deans and Abbott, 2010). Moreover,
there is an increased risk of obstetric complications after successful
hysteroscopic adhesiolysis, for example abnormal placentation,
preterm delivery, uterine rupture and peripartum hysterectomy
(Deans et al., 2018).
Women of reproductive age wishing to conceive may benefit from
the IUA prevention following operative hysteroscopy. However, the
optimal anti-adhesion strategy still needs to be defined because
data from high quality studies on the effectiveness of anti-adhesion
treatment for improving reproductive outcomes are sparse and of low
quality. A Cochrane meta-analysis of five randomised controlled trials
(RCTs) has demonstrated that the use of anti-adhesion gel may
decrease the occurrence of IUAs at second-look hysteroscopy com-
pared to no treatment or placebo (odds ratio (OR) 0.37, 95%
CI [0.21–0.64]; P<0.01). The overall quality of the body of evidence
retrieved was low and data on live birth rates were lacking (Acunzo
et al., 2003; De Iacoet al., 2003; Guida et al., 2004; Do et al., 2005;
Di Sardoet al., 2011; Bosteelset al., 2017).
In summary, uncertainty remains on the effectiveness of the use of
anti-adhesion barrier gels following operative hysteroscopy for women
wishing to conceive. In order to address this knowledge gap, our
group has designed the AGNOHSTIC trial (Anti-adhesion Gel versus
No gel following Operative Hysteroscopy prior to Subsequent fertility
Treatment or timed InterCourse).
Outcomes
The primary endpoint of the study is conception leading to live birth,
measured at 30 weeks after randomisation.
Secondary endpoints are time to conception, rates of clinical
pregnancy, miscarriage and ectopic pregnancy 30 weeks after receiving
allocated treatment, IUA rate and course of pregnancy.
For the definition of the reproductive outcomes we have followed
the guidance of The International Committee for Monitoring Assisted
Reproductive Technology (ICMART) (Zegers-Hochschild et al., 2009).
Live birth is defined as the delivery of at least one live foetus after 20
completed weeks of gestation, that resulted in at least one live baby.
WHAT DOES THIS MEAN FOR PATIENTS?
Women wishing to conceive may suffer from abnormalities (pathologies) inside the uterus that will distort the normal cavity. These abnor-
malities may be, for example, polyps (or outgrowths) on the inner lining of the uterus, benign tumours that can deform the uterine cavity,
intrauterine adhesions (IUAs), which are scar tissues that stick the uterine walls together, or placental and/or foetal tissue that remains
in the uterus after a miscarriage, planned termination, or preterm/term delivery). The presence of these pathologies may affect women’s
fertility. By performing an operative hysteroscopy, which is an inspection of the uterine cavity using an endoscope introduced through the
cervix, a diagnosis of intrauterine pathology can be made followed by surgical interventionto restore the womb to its normal shape.
This procedure is a keyhole surgery in which the pathology is removed through the vagina. One of the possible complications for this
type of surgery is the development of scar tissue (IUAs). This complication may also affect women’s fertility.
The use of an anti-adhesion gel, administered into the uterus following the operative hysteroscopy, can decrease scar tissue formation.
The goal of this trial is to investigate whether the application of the anti-adhesion gel will increase the chance of a successful pregnancy.
There is currently no information available on this topic, and that is what we want to investigate.






































































..We will count the delivery of singleton, twin or multiple pregnancies
as one live birth.
Time to pregnancy is defined as the time from receiving allocated
treatment to the date of conception retrospectively determined based
on the crown-rump length measurement by a first-trimester ultra-
sound (US).
Clinical pregnancy is defined as an US visible gestational sac. It
includes ectopic pregnancy. We count multiple gestational sacs as one
clinical pregnancy.
Miscarriage is defined as spontaneous loss of pregnancy before 20
completed weeks of gestation, or if gestational age is unknown, a
birthweight of less than 400 gram.
Ectopic pregnancy is defined as a pregnancy in which implantation
takes place outside the uterine cavity.
IUAs are measured at second-look hysteroscopy in women that
failed to conceive during the follow-up period. The severity of the
adhesions is scored according to the American Fertility Society (AFS)
classification (Buttramet al., 1988).
The course of pregnancy is registered in all women who conceive
during the follow-up period, leading to a pregnancy beyond 20 weeks
of gestation. Items of interest include pre-eclampsia, preterm birth,
stillbirth, low/very low birthweight, caesarean section rate and neona-
tal complications (respiratory distress syndrome, intrapartum asphyxia,
neonatal seizures, admission to the neonatal intensive care unit, con-
genital malformations).
Table I provides an overview of the outcome measures.
Materials and methods
Study design
The AGNOHSTIC trial is a multicentre, pragmatic, parallel group, su-
periority, blinded RCT.
Ethical review and trial registration
The study was approved by the central (Ghent University Hospital
(670), EC/2019/0100) and local Ethical Committees of the participat-
ing centres. Written informed consent of the participants will be
obtained before randomisation. The study protocol has been regis-
tered at Clinicaltrials.gov (NCT03880435, March 19, 2019).
Patient population
We will include women of reproductive age (18–47 years) wishing to
conceive (spontaneously or by fertility treatment) and scheduled for
operative hysteroscopy to treat intrauterine pathology (endometrial
polyps, myomas with uterine cavity deformation, uterine septa, IUAs
or RPOC). A CONSORT flow chart will be provided.
The mode of conception is in accordance with standard clinical
practice in Belgium. Because of the pragmatic character of the trial,
women will be allowed to switch from category A (spontaneous con-
ception) to category B (fertility treatment) or switch to a different
treatment within category B based on medical indications.
Intrauterine pathology will be detected by US, saline-infusion-
sonography (SIS), MRI or hysterosalpingography and confirmed by di-
agnostic hysteroscopy according to standard clinical practice in
Belgium. If in exceptional circumstances the diagnostic hysteroscopy
cannot be done and/or it is very likely that pathology is present based
on other imaging techniques (for example MRI), the woman will be
considered eligible and operative hysteroscopy will be scheduled.
Endometrial polyps are focal endometrial outgrowths containing
glands, stroma and blood vessels (Clark and Stevenson, 2017). They
appear as hyperechogenic structures on US with regular contours, oc-
cupying the uterine cavity, surrounded by a small hypoechogenic halo.
Colour Doppler can be used to detect the vascular stalk.
Myomas derive from myometrial cells and they may protrude into
the uterine cavity (Emanuel, 2015). They are classified according to
their anatomical location (PALM-COEIN classification) and in this study
myomas with cavity deformation, suitable for resection by hysteros-
copy, will be included (Munro et al., 2011). These are submucosal my-
omas type 0, 1 and 2 (entirely within the uterine cavity, <50% and
50% myometrial extension, respectively), and intramural myomas
sufficiently large to distort the uterine cavity (hybrid myomas type 2–5)
suitable for complete resection by hysteroscopy. The extent of cavity
protrusion is clinically relevant for predicting the successful outcome of
hysteroscopic myomectomy (Keltz et al., 2015).
A uterine septum is a congenital uterine malformation. According to
the ESHRE/European Society for Gynaecological Endoscopy classifica-
tion system for female genital tract congenital anomalies, it is defined
............................................................................................................................................................................................................................
Table I Overview of outcome measures in a randomised controlled trial of anti-adhesion gel versus no gel following
operative hysteroscopy in women who wish to conceive.
Outcome measures Endpoints Time period
Primary outcome Conception leading to live birth At 30 weeks after randomization
Secondary outcome Time to conception <30 weeks after receiving treatment allocation
Clinical pregnancy <, >30 weeks after receiving treatment allocation
Miscarriage <, >30 weeks after receiving treatment allocation
Ectopic pregnancy <, >30 weeks after receiving treatment allocation
Intrauterine adhesions <, >30 weeks after receiving treatment allocation
Course of pregnancy >30 weeks after receiving treatment allocation
Direct health-related costs 30 weeks after randomization
































































































as a uterus with a normal outline and an internal indentation at the
fundal midline exceeding 50% of the uterine wall thickness (Class U2)
(Grimbizis et al., 2013).
IUAs, scar tissue that sticks the uterine walls together, are classified
according to the AFS classification (Buttramet al., 1988).
RPOC consist of intrauterine tissue that develops after conception
and persists after miscarriage, termination of pregnancy, vaginal deliv-
ery or caesarean section (Sellmyer et al., 2013).
The presence of extrauterine pathology that may affect women’s
fertility is allowed.
Women will be excluded if they are younger than 18 years or
48 years or older, if they have a known allergy to auto-crosslinked
polysaccharide (ACP) gel or vaginal ultrasound gel, if they have an ac-
tive infection of the genital tract proven by genital swabs for PCR
(Chlamydia, gonorrhoea) or endometrial biopsy (endometritis), both
performed if suspected based on clinical symptoms (abdominal pain,
vaginal discharge or bleeding problems), if other myomas [PALM-
COEIN classification type 3 and 4 intramural (entirely in the myome-
trium with or without endometrial contact, respectively), types 5–7
subserosal (protruding towards the abdominal cavity with <,  50%
myometrial extension or pedunculated, respectively) and type 8 other
(cervical, parasitic)] are present as the sole uterine pathology, if differ-
ent types of intrauterine pathology are present preoperatively, if they
have no pregnancy wish, and if they already have participated in the
trial.
Recruitment procedure
Women attending Belgian hospitals, fulfilling the inclusion criteria will
be invited to take part in the study. Initially, recruitment was started in
six centres (Ghent University Hospital, University Hospital Brussels,
University Hospital Leuven, Cliniques Universitaires Saint-Luc Brussels,
Centre HospitalierUniversitaire Liège and Imelda Hospital Bonheiden).
To speed up the recruitment, an additional centre (Jessa Hospital
Hasselt) joined the group in 2020.
Recruitment started in April 2019 and is ongoing. The planned study
period will be 4.5 years.
Randomisation
All eligible women who provided written informed consent will be
randomised from 1 day up to 1 hour before the operative hysteros-
copy. The study is a parallel-group RCT with a 1:1 allocation ratio and
stratified randomisation with computer generated random permuted
blocks of variable sizes to avoid that the surgeon may predict the
treatment allocation.
The stratification factors are centre(seven categories) and type of
pathology treated by hysteroscopy (five categories).
Study drug
The intervention under study is the application of an anti-adhesion gel,
namely HyalobarrierVR gel endo (Nordic Pharma), after the complete
removal of intrauterine pathology (endometrial polyps, myomas with
uterine cavity deformation, uterine septa, IUAs or RPOC) by hysteros-
copy. A second operation will be planned in case of incomplete pa-
thology removal. The anti-adhesion gel is sterile, transparent and highly
viscous, and made from ACP obtained by condensation of hyaluronic
acid. Due to its viscosity, it keeps the surrounding tissue separate dur-
ing the recovery period after surgery. Seven days after application in
the uterine cavity, the gel is fully absorbed (Renier et al., 2005). In the
uterine cavity it is shown to remain in situ for at least 72 hours
(Acunzo et al., 2003). Yang et al.(2013) showed a different endome-
trial healing process for various hysteroscopic procedures.The shortest
time period occurred after polypectomy (1–2 months), and the longest
time period was seen after myomectomy. Whether the time frame of
72 hours is sufficient remains to be seen. The effectiveness of
HyalobarrierVR gel has been demonstrated during surgical procedures
in the abdomen and pelvis during clinical studies(De Iacoet al., 2001;
Acunzo et al., 2003; Pellicano et al., 2003, 2005; Pucciarelli et al.,
2003; Guida et al., 2004; Mais et al., 2006, 2012; Metwally et al.,
2007). It is indicated for use in laparoscopic and hysteroscopic proce-
dures and is available as a single-use disposable syringe. Each syringe
contains 10 ml of sterile gel containing 30 mg of ACP per ml. For ad-
ministration, individually packaged cannulas of 30 cm length are
enclosed. All reportable adverse events will be recorded in the
patient’s file and in the electronic Case Report Form (e-CRF) between
randomisation and the last trial related activity. Medical events that oc-
cur between signing of the Informed consent and the randomisation
will be documented on the medical and surgical history section and
concomitant diseases page of the e-CRF. Additionally, all Serious
Adverse Device Effects (SADE), Unanticipated Serious Adverse Device
Effects (USADE), incidents and other significant safety issues will be
reported immediately but no later than 3 calendar days after investiga-
tional site study personnel’s awareness of the event to the sponsor
and chief investigator. A detailed listing of our safety reporting is
shown in Supplementary File S1.
No gel will be applied in the uterine cavity of women assigned to
the control group.
The patient, fertility physician and gynaecologist performing the
second-look hysteroscopy will be unaware of the allocated treatment.
To ensure blinding, and to rule out a treatment effect of placebo gel
applied in the uterine cavity, sterile US gel will be applied into the va-
gina in both treatment arms. The surgeons doing the operative hyster-
oscopy cannot be blinded. If the fertility physician or the gynaecologist
doing the second-look hysteroscopy has also performed the operative
hysteroscopy, blinding will be assured by notification of treatment allo-
cation to another caretaker (colleague gynaecologist or resident) after
the surgeon has left the operating room. The gel will subsequently be
applied by this caretaker. The biostatistician and the study nurses
were blinded and did not make any decisions with respect to the fur-
ther treatment and/or follow-up of the study participants.
Co-treatment with hormonal medication may be given or repeated
SIS or hysteroscopy may be scheduled for severe IUAs, according to
the standard practice of the participating centre. This decision should
be made before the notification of the treatment allocation.
Follow-up
The trial flow chart is shown in Fig. 1. According to local practice,
3–6 weeks after the operative hysteroscopy with complete pathology
removal, women will be scheduled for a postoperative visit (telephone
or physical) or a second-look hysteroscopy. Subsequently, they may
start trying to conceive by regular sexual intercourse or fertility treat-
ment (4–6 cycles ovulation induction, 4–6 cycles controlled ovarian























..stimulation or 4–6 cycles IUI or 3 embryo transfers). Women will be
contacted every month to check if they are pregnant.
The short-term follow-up ends 30 weeks after randomisation for
the primary endpoint. This is in concordance with the CONSORT
guidelines (Moher et al., 2010). Secondary endpoints, namely time
to conception and rates of clinical pregnancy, miscarriage and ec-
topic pregnancy, are measured 30 weeks after receiving allocated
treatment. In all women that fail to conceive within this timeframe,
a second-look hysteroscopy will be scheduled within 2–6 weeks to
check for IUAs.
The long-term follow-up starts if the patient is pregnant,
within 30 weeks after receiving allocated treatment. Women will be
contacted every trimester.
An overview of the collected data is shown in Supplementary
Files S2–S10.
Statistical analysis
Continuous variables will be summarised with descriptive statistics
(mean and SD for data that are approximately normally distributed
Figure 1. Trial flow chart for a randomised controlled trial of anti-adhesion gel versus no gel following operative hysteroscopy in women who wish to
conceive.IUAs, intrauterine adhesions; RPOC, retained products of conception; OI, ovulation induction;COS, controlled ovarian stimulation; US, ultrasound.
































































































and median and interquartile range otherwise). Categorical data will
be presented as frequency and percentage.
The primary endpoint, conception leading to live birth 30 weeks af-
ter randomisation, will be analysed using binary logistic regression tak-
ing centre and type of pathology into account. The estimated OR with
95% CI will be reported.
The secondary endpoint, time to conception, will be analysed using
Kaplan–Meier analyses and randomisation groups will be compared
using a Cox model adjusting for centre and type of pathology. The
intervention effect will be expressed as a hazard ratio.
The secondary endpoints, clinical pregnancy, miscarriage, ectopic
pregnancy and IUA rates, will be analysed similarly as the primary
endpoint. However, the variables describing the course of pregnancy
will be expressed as OR or mean difference.
The primary analysis will be the intention-to-treat analysis (ITT)
analysis. All participants will be included in the analysis in the groups to
which they were originally assigned, regardless of what subsequently
occurred. Multivariate imputation by fully conditional specificationwill
be used for outcome data that are missing (Moher et al., 2010). The
predictors used for the imputation model will be randomisation group,
centre, intended mode of fertility treatment, change in fertility treat-
ment (yes/no), type of pathology treated by operative hysteroscopy,
age of the participant, weight and height of the participant, duration of
infertility, type of infertility (primary or secondary), cause of infertility
(ovulatory disorder, male factor, tubal factor, unexplained, endometri-
osis) and smoking (yes/no).
Two sensitivity analyses will be performed. First, ITT with non-
response imputation. Second, a per protocol analysis, excluding all
women in the ITT population who no longer wish to conceive, who
have an incomplete follow-up or who received a treatment different
from the randomised group.
Two subgroup analyses will be performed. First, to explore whether
the effect of ACP gel on the primary endpoint might differ between
types of pathology. This analysis is similar to that of the primary end-
point and a stratification factor ‘type of pathology treated by hysteros-
copy’ will be added as a categorical predictor variable. An interaction
term between type of pathology and randomisation group will be in-
cluded in the model. Second, two scenarios are considered: no change
in fertility treatment and change in fertility treatment. These analyses
are similar to that of the primary endpoint. All subgroup analyses will
be performed both on the ITT and the protocol-compliant sample.
Statistical analyses will be performed with the use of SAS (SAS
Institute, Cary, NC, USA) and R (R Core Team, 2019).
Sample size
Sample size calculation for the logistic regression on the primary end-
point was performed in SAS version 9.4 using the power procedure.
The alternative hypothesis states that the proportion of pregnancies
leading to live birth at 30 weeks after randomisation is 45% in the con-
trol group (no ACP gel) and 60% in the intervention group (ACP gel).
The sample size analysis was based upon our own database regard-
ing the pregnancy rate after operative hysteroscopy performed from
2011 until 2016. Based on these data, a pregnancy rate of 45% was
expected in the control group. The pregnancy rate for the intervention
group was expected to be 60%. This percentage is based on expert
opinion in combination with the pregnancy rate seen in a subgroup of
single/lesbian women and male infertility in the same database.
Based upon the Belgian Register for Assisted Procreation (BELRAP
database), the cumulative clinical pregnancy rate after six IUIs and three
embryo transfers was 47% and 46.5%, respectively, regardless of age.
We need 399 participants to achieve 85% power at a significance
level of 5%, to demonstrate or refute an increase from 45% to 60%.
We expect a drop-out rate of a maximum 10% after randomisation,
leading to a sample size of 444 participants that should be randomised.
Sample size analysis per pathology was not performed because of
the pragmatic design.
Discussion
Operative hysteroscopy to treat intrauterine pathologies is a frequently
performed procedure in women wishing to conceive. Following the
procedure, IUAs may develop and this may compromise women’s fer-
tility prognosis.
A Cochrane systematic review on the effectiveness of anti-adhesion
methods following operative hysteroscopy in women wishing to con-
ceive, to improve key reproductive outcomes or to decrease IUAs has
shown that the quality of evidence was low (Bosteelset al., 2017).
The Prevention of Adhesions Post Abortion (PAPA) trial is the larg-
est multicentre RCT comparing the application of ACP gel after dila-
tion and curettage (D&C) for miscarriage with no treatment in a
population at risk for IUAs (defined as at least one D&C in the his-
tory) (Hooker et al., 2017). The IUA rate was significantly lower in the
ACP group compared to the control group. Moreover, the mean ad-
hesion score and the amount of moderate to severe IUAs, assessed
by the AFS scoring system, were significantly lower after the applica-
tion of ACP gel. Thus, ACP gel may be of benefit in a specific sub-
group of women scheduled for D&C for miscarriage with at least one
D&C in the history.
The authors have recently reported the long-term follow-up, includ-
ing fertility and obstetric outcomes, of the women who participated in
the PAPA trial (Hooker et al., 2018). Questionnaires were sent 3, 6
and 12 months after D&C. The rates of pregnancy, miscarriage and
live birth, and time to conception were not statistically different.
However, the PAPA trial has some important limitations. First, the
study was not powered for reproductive outcomes. Second, second-
look hysteroscopy revealed more IUAs in the control group, and these
were removed because it was considered to be unethical not to per-
form hysteroscopic adhesiolysis.
Currently, in Belgium, anti-adhesion gels are only partially reim-
bursed in specific conditions (<40 years old, wishing to conceive,
scheduled for laparoscopy or laparotomy) and there is no reimburse-
ment for the use in hysteroscopy.
The AGNOHSTIC trial aims to provide the evidence that a de-
crease in IUA formation by application of ACP gel following operative
hysteroscopy, improves reproductive outcomes in women wishing to
conceive. If the AGNOHSTIC trial succeeds, we plan to perform a
health-economic analysis in order to emphasize the need for reim-
bursement. This will be the topic of a separate publication.
This study has some important strengths. To our knowledge, this is
the first large multicentre and well-designed RCT focusing on the influ-
ence of ACP gel on reproductive outcomes. Our study is powered to
































































































detect a difference in the primary study outcome, conception leading
to live birth, measured at a fixed time point, namely 30 weeks after
randomisation. Measuring ‘live birth’ as primary endpoint would imply
a longer follow-up period and a risk of multiple outcomes in one pa-
tient, different modes of conception per patient and risk of drop-out.
It would make the design of this pragmatic trial more complicated.
Moreover, women will be well monitored during the short-term fol-
low-up by monthly contact and every trimester during long-term fol-
low-up instead of using questionnaires, which may be accompanied by
recall bias.
Furthermore, patient representatives are involved and report to the
trial steering committee.
This study also has some limitations. Our study population will be a
mix of women trying to conceive by regular sexual intercourse or fer-
tility treatment. This composition was chosen because of the prag-
matic character of our study, to meet the recruitment options of all
the involved centres, and to reach our large sample size in an accept-
able time period.
Women will be included until the age of 47 years and it is known
that age is an important predictor for fertility. The present study uses
the stratified randomization method. However, age is not included as
a covariate: this is a pragmatic study and the Belgian law allows trans-
fer of frozen embryos until 47 years. The ‘bottom line’ of the trial is to
study whether the application of ACP gel subsequent to operative hys-
teroscopy in women wishing to conceive improves their reproductive
outcome. Co-treatment with hormonal medication may be given or
repeated SIS or hysteroscopy may be scheduled for severe IUAs,
according to the standard practice of the participating centre. Thus,
we avoid the possibility that women with severe IUAs allocated to the
control group do not receive a postoperative anti-adhesion treatment.
At 3–6 weeks after the operative hysteroscopy with complete pa-
thology removal, women may be scheduled for second-look hysteros-
copy, according to local practices. IUAs on second-look hysteroscopy
will be treated by adhesiolysis. This may impact the primary outcome
in favour of the control group. However, both issues, namely addi-
tional anti-adhesion treatment and adhesiolysis, will be solved because
stratification is performed per centre and pathology.
Lastly, to be in line with the CONSORT guidelines, the primary
endpoint will be measured at a pre-specified time point, namely
30 weeks after randomisation. Only if the intrauterine pathology is
completely removed, the allocated treatment will be announced and
applied. Otherwise, women are scheduled for a second operative hys-
teroscopy followed by the allocated treatment. Thus, their timeframe
to become pregnant will be shorter.
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